Sidebar,

The variants of Covid provide a good opportunity for RVX (assuming a successful Covid trial). It looks like the Oxford vaccine is not very effective against the SA variant: 'A study outlining early trials, first reported by the Financial Times, suggests the vaccine offered "minimal protection" against mild and moderate disease caused by the variant, the University of Oxford said.' https://www.bbc.com/news/uk-55967767

It's not unreasonable to think that there will be additional mutations that current vaccines either a) won't protect against at all, or b) will offer limited protection.

The UK's minister of vaccines has the following view of Covid vaccinations going forward: "We see very much probably an annual or booster in the autumn and then an annual (jab), in the way we do with flu vaccinations where you look at what variant of virus is spreading around the world, rapidly produce a variant of vaccine and then begin to vaccinate and protect the nation."

If RVX is able to offer a drug that reduces serious side effects of Covid, as well as current and future variants, it sounds like there may be a significant (and continuous) market for it.